Key Principles and Recommended Regimens for First-line Antiretroviral Therapy
Summary
- The phase III ECHO and THRIVE trials compared rilpivirine vs efavirenz in treatment-naive patients[Cohen 2011; Molina 2011]
- Rilpivirine was found to be noninferior to efavirenz in each trial but was less effective than efavirenz among the stratum of patients with baseline of HIV-1 RNA > 100,000 copies/mL
- The phase III open-label StaR trial compared coformulated emtricitabine/rilpivirine/tenofovir DF to efavirenz/emtricitabine/tenofovir DF[Cohen 2011]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content